Clofazimine is an antimycobacterial drug primarily used for the treatment of leprosy (especially lepromatous leprosy) and erythema nodosum leprosum reactions. Despite its significant efficacy, potential side effects and special precautions must be closely monitored during medication.
What are the Side Effects of Clofazimine?
Skin and Body Fluid Discoloration
Occurrence Rate: 75%-100% of patients experience orange-red to brown-black pigmentation in the skin, conjunctiva, tears, sweat, sputum, urine, and feces.
Characteristics: The pigmentation may persist for several months or even years and gradually fades after discontinuing the drug.
Other Skin Reactions: Ichthyosis, dry skin, and pruritus (occurrence rate: 8%-28%); skin rashes and photosensitive dermatitis are occasionally observed.
Gastrointestinal Reactions
Typical Symptoms: Abdominal pain, diarrhea, nausea, and vomiting (occurrence rate: 40%-50%).
Long-term Risks: The drug may deposit in the intestinal mucosa, leading to intestinal obstruction, gastrointestinal bleeding, and even splenic infarction, which requires close monitoring.
Other Reactions
Laboratory Abnormalities: Elevated blood glucose, accelerated erythrocyte sedimentation rate (ESR), and abnormal liver function indicators.
Nervous System: Dizziness, headache, and fatigue.
Severe Side Effects of Clofazimine Requiring Vigilance
Gastrointestinal Obstruction and Bleeding
Mechanism: Clofazimine crystals deposit in the intestinal mucosa, which may cause intestinal obstruction and splenic infarction; severe cases can be fatal.
Countermeasures: If a patient experiences persistent abdominal pain, vomiting, or hematochezia, the drug must be discontinued immediately and medical attention sought.
QT Interval Prolongation and Arrhythmia
Risk Scenarios: When the dose exceeds 100mg per day or the drug is used in combination with other QT-prolonging drugs (e.g., bedaquiline).
Monitoring Requirements: Regular electrocardiogram (ECG) examinations are required during medication. If the corrected QT interval using Fridericia's formula (QTcF) is ≥500ms or syncope occurs, the drug should be discontinued.
Precautions for Clofazimine Administration
Medication in Special Populations
Pregnant Women: The drug should only be used when there is a clear indication, as it may cause skin pigmentation in the fetus.
Lactating Women: Clofazimine can be excreted in breast milk, so the benefits and risks must be weighed.
Children and Elderly Patients: The safety has not been fully established, and individualized assessment is required.
Drug Interactions
CYP3A4 Substrates: Clofazimine may increase the plasma concentration of CYP3A4 substrates, so toxicity monitoring is necessary (e.g., for certain anticoagulants and immunosuppressants).
QT-Prolonging Drugs: Concurrent use should be avoided; if necessary, enhanced ECG monitoring is required.
Patient Education
Dietary Advice: Take the drug with meals to reduce gastrointestinal irritation.
Adherence: Emphasize regular medication to prevent drug resistance.
Follow-up Requirements: Conduct regular re-examinations of liver and kidney function, ECG, and mental status.
